Literature DB >> 20503411

Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments.

Steven Van Laere1, Ridha Limame, Eric A Van Marck, Peter B Vermeulen, Luc Y Dirix.   

Abstract

Stem cells are pluripotent cells, with a large replicative potential, which perform normal physiological functions such as tissue renewal and damage repair. However, because of their long lifespan and high replicative potential, stem cells are ideal targets to accumulate multiple mutations. Therefore, they can be regarded as being responsible for the initiation of tumor formation. In the past, numerous studies have shown that the presence of an elaborate stem cell compartment within a tumor is associated with aggressive tumor cell behavior, frequent formation of metastases, resistance to therapy, and poor patient survival. From this perspective, tumors from patients with inflammatory breast cancer (IBC), an aggressive breast cancer subtype with a dismal clinical course, are most likely to be associated with stem cell biology. To date, this hypothesis is corroborated by evidence resulting from in vitro and in vivo experiments. Both gene and microRNA expression profiles highlighted several stem cell-specific signal transduction pathways that are hyperactivated in IBC. Also, these stem cell-specific signal transduction pathways seem to converge in the activation of nuclear factor-kappa B, a molecular hallmark of IBC, and induction of epithelial-to-mesenchymal transition. Recently, the latter mechanism was identified as a prerequisite for the induction of stem cell characteristics in breast cancer cells. Copyright 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20503411     DOI: 10.1002/cncr.25180

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer.

Authors:  Adam R Wolfe; Rachel L Atkinson; Jay P Reddy; Bisrat G Debeb; Richard Larson; Li Li; Hiroko Masuda; Takae Brewer; Bradley J Atkinson; Abeena Brewster; Naoto T Ueno; Wendy A Woodward
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

Review 2.  Inflammatory breast cancer: what we know and what we need to learn.

Authors:  Hideko Yamauchi; Wendy A Woodward; Vicente Valero; Ricardo H Alvarez; Anthony Lucci; Thomas A Buchholz; Takayuki Iwamoto; Savitri Krishnamurthy; Wei Yang; James M Reuben; Gabriel N Hortobágyi; Naoto T Ueno
Journal:  Oncologist       Date:  2012-05-14

3.  Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.

Authors:  Amanda Valeta-Magara; Abhilash Gadi; Viviana Volta; Beth Walters; Rezina Arju; Shah Giashuddin; Hua Zhong; Robert J Schneider
Journal:  Cancer Res       Date:  2019-05-01       Impact factor: 12.701

4.  Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.

Authors:  Maurice P H M Jansen; Leen Sas; Anieta M Sieuwerts; Caroline Van Cauwenberghe; Diana Ramirez-Ardila; Maxime Look; Kirsten Ruigrok-Ritstier; Pascal Finetti; François Bertucci; Mieke M Timmermans; Carolien H M van Deurzen; John W M Martens; Iris Simon; Paul Roepman; Sabine C Linn; Peter van Dam; Marleen Kok; Filip Lardon; Peter B Vermeulen; John A Foekens; Luc Dirix; Els M J J Berns; Steven Van Laere
Journal:  Mol Oncol       Date:  2015-03-04       Impact factor: 6.603

5.  Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.

Authors:  Helen O Oladapo; Michael Tarpley; Scott J Sauer; Kezia A Addo; Shalonda M Ingram; Dillon Strepay; Ben K Ehe; Lhoucine Chdid; Michael Trinkler; Jose R Roques; David B Darr; Jodie M Fleming; Gayathri R Devi; Kevin P Williams
Journal:  Cancer Lett       Date:  2017-09-28       Impact factor: 8.679

6.  Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration.

Authors:  Z I Thomas; W Gibson; J Z Sexton; K M Aird; S M Ingram; A Aldrich; H K Lyerly; G R Devi; K P Williams
Journal:  Br J Cancer       Date:  2011-04-19       Impact factor: 7.640

7.  Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model.

Authors:  Lara Lacerda; Bisrat G Debeb; Daniel Smith; Richard Larson; Travis Solley; Wei Xu; Savitri Krishnamurthy; Yun Gong; Lawrence B Levy; Thomas Buchholz; Naoto T Ueno; Ann Klopp; Wendy A Woodward
Journal:  Breast Cancer Res       Date:  2015-03-20       Impact factor: 6.466

8.  Polycyclic aromatic hydrocarbon-induced signaling events relevant to inflammation and tumorigenesis in lung cells are dependent on molecular structure.

Authors:  Ross S Osgood; Brad L Upham; Thomas Hill; Katherine L Helms; Kalpana Velmurugan; Pavel Babica; Alison K Bauer
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

Review 9.  The interaction between ER and NFκB in resistance to endocrine therapy.

Authors:  Leen Sas; Filip Lardon; Peter B Vermeulen; Jan Hauspy; Peter Van Dam; Patrick Pauwels; Luc Y Dirix; Steven J Van Laere
Journal:  Breast Cancer Res       Date:  2012-08-31       Impact factor: 6.466

10.  EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.

Authors:  Bisrat G Debeb; Yun Gong; Rachel L Atkinson; Nour Sneige; Lei Huo; Ana Maria Gonzalez-Angulo; Mien-Chie Hung; Vicente Valero; Naoto T Ueno; Wendy A Woodward
Journal:  J Exp Clin Cancer Res       Date:  2014-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.